Unsubscribe

A message from Market Jar, Inc

Dear Fellow Trader,

In every tech cycle, there's a moment when utility replaces speculation.

That moment just arrived for digital assets.

A newly listed ETF brings the focus back to purpose — a settlement network designed to move value across currencies in seconds with near-zero friction.

And it does it through a wrapper investors already understand.

No wallets. No private keys. No complexity.

Just a single-asset ETF you can buy, sell, and rebalance like any other position.

Qualified custodians handle safekeeping. Recognizable administrators keep the records. A plain-English 0.50% fee covers it.*

Recent digital-asset ETFs proved the demand for simplicity — volume surged, liquidity deepened, and institutions took notice.

This launch takes that same discipline and applies it to the payments network at the core of real-time finance.

If faster settlement is the future, this is how you hold it — without leaving your brokerage account.

Discover the ETF's name and ticker here.

*Brokerage commissions apply and will reduce returns

For standardized returns of the Canary XRP ETF, please visit [XRP ETF - Canary Capital]. Past performance does not guarantee future results.

The Fund's investment objectives, risks, charges and expenses should be considered before investing. The prospectus contains this and other important information, and it may be obtained at https://etfs.canary.capital/XRPC/prospectus/. Read it carefully before investing.

The Fund is not an investment company registered under the Investment Company Act of 1940 (the "1940 Act"), and therefore is not subject to the same regulatory requirements as mutual funds or traditional ETFs registered under the 1940 Act.

Investing Involves Significant Risk. The loss of principal is possible. Canary XRP ETF (the "Fund") may not be suitable for all investors. This document does not constitute a recommendation of any investment strategy or product for a particular investor. Investors should consult a financial advisor/financial consultant before making any investment decisions.

The fund is new with a limited operating history.

Digital assets, such as XRP, are a relatively new asset class, and the market for digital assets is subject to rapid changes and uncertainty. Digital assets are largely unregulated and digital asset investments may be more susceptible to fraud and manipulation than more regulated investments.

XRP is subject to unique and substantial risks, including significant price volatility and lack of liquidity, and theft. The value of an investment in the Fund could decline significantly and without warning, including to zero. XRP is subject to rapid price swings, including as a result of actions and statements by influencers and the media, changes in the supply of and demand for digital assets, and other factors. There is no assurance that XRP will maintain its value over the long-term. The Fund is not actively managed and will not take any actions to take advantage, or mitigate the impacts, of volatility in the price of XRP. An investment in the Fund is not a direct investment in XRP. Investors will not have any rights that XRP holders have and will not have the right to receive any redemption proceeds in XRP. Shares of the Fund are generally bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Only Authorized Participants may trade directly with the Fund and only large blocks of Shares called "creation units." Your brokerage commissions will reduce returns.

Paralel Distributors LLC serves as the marketing agent. Paralel is unaffiliated with Canary Capital and Native Ads.

Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

Today's editorial pick for you

3 Year-End Stocks to Speculate on New Year’s Resolutions

Posted On Nov 17, 2025 by Chris Markoch

As hard as it is to believe, the end-of-the-year sprint is almost here. Before the holiday rush starts, it’s time for you to consider some year-end stocks that may be profitable speculative trades.

In the next few weeks, there's Thanksgiving, where we eat until we pass out from too much tryptophan. Then, the December holidays increase our calorie consumption. And before you know it, you'll be watching the ball drop.

And as that’s happening, as millions of us do, we promise next year will be different.

Around this time of year, about 90% of us, according to Johns Hopkins Medicine, make a resolution to lose weight, diet, and exercise more. As the popularity of GLP-1 drugs shows, millions of us are worrying about our expanding waistlines and promising ourselves that next year will be different.

But this isn’t an article about the obesity epidemic or a search for biotechnology stocks. For many people, weight loss comes from joining Weight Watchers or Medifast. We may even join a gym. And that’s a good place to start our hunt for year-end stocks to buy.

Year-End Stocks: Planet Fitness

Planet Fitness (NYSE: PLNT) is an almost too-obvious example in the category of year-end stocks. For the last several years, PLNT stock tends to take off around the holidays. We saw that pattern in late 2020, in late 2021, in late 2022, and again in 2023 and 2024. We're seeing it happen again now because of a revenue beat.

Specifically, revenue of $330.3 million, up 13% year over year, beat by $6.87 million. For 2025, PLNT expects revenue to grow 11% from prior estimates of 10%. It expects adjusted EBITDA to increase 12% from prior estimates of 10%. And it expects adjusted net income to jump 13% to 14% from a prior range of 8% to 9%.

Analysts have taken notice and have started to increase their price targets for PLNT stock. One of the most bullish targets comes from Morgan Stanley, which gives the stock a $125 price target. That’s nearly $10 higher than the consensus target of $116.54.

Year-End Stocks: Peloton Interactive

Another hot entry in the category of year-end stocks to buy is Peloton Interactive (NASDAQ: PTON). Peloton stock is down about 14% in 2025 as of this writing. However, it’s up about 50% since getting obliterated in the “Liberation Day” tariff sell-off.

And PTON’s recovery from its April low is more than just a technical anomaly. The stock has managed to gain a bull at Goldman Sachs, which views PTON stock as a buy opportunity with an $11.50 price target. That’s above the consensus price of $9.95, which is by itself 32% above the PTON stock price as of this writing.

To reignite sales growth, Peloton is revamping its equipment, adding a new commercial unit, and raising subscription prices. Morgan Stanley believes that by raising prices, the company could rake in an additional $180 million in EBITDA.

PTON is also starting to see positive changes on its balance sheet, producing significant free cash flow of $324 million. Plus, PTON just cut its net debt by 43%, which is a healthy sign of a turnaround.

The company also expects to see further improvements in profits, gross margins, and its free cash flow numbers moving forward.

Year-End Stocks: Global X Health Tech ETF

While Planet Fitness and Peloton may set up as solid swing trades, you may be interested in year-end stocks that you can own for the long term. That could lead you to healthcare technology stocks, and that may mean looking at exchange-traded funds (ETFs).

The Global X HealthTech ETF (NASDAQ: HEAL) is an attractive option for investors who want to go this route. The fund targets companies involved in AI-enabled drug discovery, smart medical devices, tech-enabled consumer healthcare, and healthcare analytics and software solutions. Some of its 40 holdings include Tempus AI, Hims & Hers Health, Doximity, ResMed, and iRhythm Technologies.

The HEAL ETF is flat in 2025 and is down sharply since it debuted in late 2020. The risk is that several stocks in the fund may face FDA scrutiny over GLP-1 drugs. However, the HEAL stock price on November 14 may be confirming a level of support near its 52-week low.

The fund has an attractive expense ratio of around 0.50%.

This message is a PAID ADVERTISEMENT for Canary XRP ETF (NASDAQ:XRPC) from Market Jar Media Inc. StockEarnings, Inc. has received a fixed fee of $6000 from Market Jar Media Inc for multiple Dedicated Email Sends, Newsletter Sponsorships and SMS Sends between Nov 20, 2025 and Nov 26, 2025. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either Canary XRP ETF (NASDAQ:XRPC) or Market Jar Media Inc. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Canary XRP ETF (NASDAQ:XRPC) on TradingWhisperer website for additional information about the relationship between Market Jar Media Inc and Canary XRP ETF (NASDAQ:XRPC).

Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe.

StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS
StockEarnings.com